It has been proposed that AXL inhibition can be achieved by blocking TBK1 (TANK binding kinase 1)/NF-κB pathway, a key signal pathway of immune cells, changes the composition of chemokines and cytokines in tumor microenvironment, making tumor sensitive to treatment [96]. This evidence concerns the gene NFKB1 and neoplasm.